Dayvigo Vaccine Interaction Profile: What Patients and Clinicians Need to Know

What Is Lemborexant and How Does It Work?

Lemborexant is a dual orexin receptor antagonist approved by the FDA in December 2019 for the treatment of insomnia in adults [1]. It blocks orexin OX1 and OX2 receptors in the brain, reducing the wake-promoting signaling of the orexin (hypocretin) system. Unlike older benzodiazepine receptor agonists, it does not broadly suppress the central nervous system; it specifically quiets the arousal pathway.

Pharmacokinetic Basics

After a 10 mg oral dose, peak plasma concentration is reached in roughly 1 to 3 hours. The mean elimination half-life is approximately 17 to 19 hours, which is clinically meaningful because residual sedation can persist into the next morning [2]. Protein binding is about 94%, and the volume of distribution is large (approximately 1,970 L), reflecting extensive tissue penetration.

The CYP3A4 Connection

Lemborexant is metabolized predominantly by CYP3A4. This single fact governs most of its clinically significant drug interactions. Any compound that strongly inhibits CYP3A4 (itraconazole, clarithromycin, ritonavir) raises lemborexant plasma exposure substantially, increasing the risk of next-day impairment. Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) reduce exposure and may blunt efficacy [2]. The FDA label states that co-administration with strong CYP3A4 inhibitors is contraindicated [2].

Do Vaccines Interact with Dayvigo?

No approved vaccine interacts pharmacokinetically with lemborexant. This is the most direct answer, and it is supported by the mechanism of both vaccines and lemborexant's metabolic pathway.

Why Vaccines Do Not Alter Lemborexant Metabolism

Vaccines, whether mRNA-based (e.g., the Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 COVID-19 vaccines), adjuvanted subunit vaccines (e.g., Shingrix), inactivated virus vaccines (e.g., Fluzone), or live-attenuated vaccines (e.g., MMRII), do not encode, produce, or release compounds that inhibit or induce hepatic CYP450 enzymes [3]. The cytochrome P450 system is a family of liver-based oxidative enzymes. Vaccine antigens and adjuvants do not reach the liver in concentrations capable of modulating these enzymes.

A review of the FDA prescribing information for lemborexant lists no vaccine as a contraindicated or cautioned co-administration [2]. The published pharmacokinetic interaction studies for lemborexant evaluated compounds known to share or affect the CYP3A4 pathway, not vaccine preparations.

The Post-Vaccination Systemic Reaction Caveat

This is where clinical nuance matters. Vaccines frequently produce systemic reactions: fever, fatigue, myalgia, and headache. These reactions reflect the intended immune activation. In ZOSTER-006 (N=15,411), Shingrix produced grade 3 systemic reactions in 11.4% of recipients after dose 1 [4]. Influenza vaccines produce fatigue and malaise in a meaningful proportion of recipients.

Fatigue and reduced alertness from post-vaccination reactions are additive with any CNS depressant, including lemborexant. A patient who feels feverish and exhausted the evening after a Shingrix injection will likely experience deeper sedation from their usual 10 mg lemborexant dose. This is a pharmacodynamic overlay, not a pharmacokinetic interaction, but the clinical outcome (excessive sedation, balance impairment, next-day grogginess) is the same from a safety standpoint.

Practical Timing Framework for Vaccination Days

1. Schedule vaccines in the morning when possible, allowing systemic reactions to declare themselves before bedtime.
2. If a patient develops a grade 2 or 3 systemic reaction (fever >38.5 °C, significant fatigue), consider holding the lemborexant dose that night or reducing to 5 mg at the prescriber's discretion.
3. Document the vaccine date in the medical record so any next-day sedation complaints can be contextualized accurately.
4. Patients should not drive or operate machinery the morning after a lemborexant dose taken during a febrile post-vaccination period.

Can I Drink Alcohol on Dayvigo?

No. The FDA label explicitly warns against combining lemborexant with alcohol. This is one of the most clinically important cautions in the prescribing information and one of the most common patient questions.

The Mechanism of Additive CNS Depression

Alcohol potentiates CNS depressants through GABAergic enhancement and NMDA receptor inhibition. Lemborexant, while not a GABA-A agonist, still reduces arousal-circuit activity. Combining the two produces additive sedation, psychomotor impairment, and the potential for respiratory depression at higher alcohol doses. In a dedicated drug interaction study cited in the FDA label, co-administration of lemborexant with alcohol impaired driving performance the next morning more than either substance alone [2].

Real-World Relevance

Even "one drink" the evening of a lemborexant dose can extend next-morning cognitive impairment. Patients who socialize in the evening and take lemborexant before bed should be counseled explicitly. The 17-to-19-hour half-life means lemborexant is still present at meaningful concentrations at 8 a.m. The next day if taken at 11 p.m. The prior night. Add alcohol metabolism time (approximately 1 hour per standard drink cleared) and the overlap period can be substantial.

Full Lemborexant Drug Interaction Profile

Understanding the complete interaction field helps clinicians contextualize where vaccines sit relative to genuinely high-risk combinations.

Strong CYP3A4 Inhibitors (Contraindicated)

The FDA label contraindicates lemborexant use with strong CYP3A4 inhibitors [2]. These include:

• Itraconazole and other azole antifungals (voriconazole, ketoconazole)
• Clarithromycin
• Ritonavir and other HIV protease inhibitors

Co-administration with itraconazole increased lemborexant AUC by approximately 4-fold in a dedicated pharmacokinetic study [2]. That level of exposure increase translates directly into prolonged and intensified sedation, with meaningful fall and impaired-driving risk.

Moderate CYP3A4 Inhibitors (Dose Adjustment Required)

Fluconazole, diltiazem, and grapefruit juice are moderate CYP3A4 inhibitors. The FDA label recommends that lemborexant not exceed 5 mg nightly when used with moderate inhibitors [2]. Grapefruit juice is specifically listed, and patients often do not identify it as a medication interaction risk.

Strong and Moderate CYP3A4 Inducers (Avoid Combination)

Rifampin reduces lemborexant exposure dramatically. In the labeling pharmacokinetic data, rifampin co-administration reduced lemborexant AUC by approximately 87%, likely eliminating therapeutic efficacy [2]. Carbamazepine, phenytoin, and St. John's Wort carry similar inductive potential. The label advises avoiding these combinations.

CNS Depressants (Additive Pharmacodynamic Risk)

Other sedative-hypnotics (zolpidem, eszopiclone, suvorexant), benzodiazepines, opioids, and certain antihistamines (diphenhydramine) all carry additive sedation risk. The FDA label specifically cautions co-use with other CNS depressants and recommends considering a dose reduction [2]. In the SUNRISE-1 trial (N=291), even the 10 mg dose of lemborexant alone produced next-morning residual sleepiness in a subset of patients; adding a CNS depressant amplifies this effect [5].

Digoxin (P-glycoprotein Substrate)

Lemborexant is a P-glycoprotein (P-gp) inhibitor in vitro. Co-administration with digoxin, a P-gp substrate with a narrow therapeutic index, requires monitoring of digoxin serum levels. The FDA label advises monitoring when these agents are used together [2].

Where Vaccines Fall in This Hierarchy

Vaccines do not appear in any tier of this interaction hierarchy. They are not CYP3A4 modulators, not CNS depressants, and not P-gp substrates or inhibitors [3]. The only relevant consideration is the transient pharmacodynamic overlay from post-vaccination systemic symptoms, as described above.

Lemborexant and Specific Vaccine Types

Influenza Vaccines

Annual influenza vaccines (inactivated and recombinant formulations) are among the most commonly administered vaccines in adults taking chronic medications. Neither inactivated influenza vaccine (e.g., Fluzone Quadrivalent) nor recombinant influenza vaccine (Flublok) contains components with CYP3A4 modulatory activity [3]. The CDC recommends annual influenza vaccination for all adults, and there is no basis to interrupt or modify lemborexant therapy around influenza vaccination [6].

Post-vaccination fatigue occurs in approximately 10 to 30% of influenza vaccine recipients. Patients should be aware that if they feel fatigued or unwell the evening of vaccination, lemborexant sedation may feel more pronounced than usual.

COVID-19 mRNA Vaccines

The Pfizer-BioNTech and Moderna mRNA vaccines produce their immunogenic effects via transient spike protein expression at the injection site and draining lymph nodes. The mRNA itself degrades within days. Neither the mRNA sequence nor the spike protein modulates hepatic CYP450 enzymes [3]. The adjuvant component of COVID-19 mRNA vaccines (lipid nanoparticles) similarly has no documented CYP3A4 modulatory effect.

Post-vaccination systemic reactions after COVID-19 boosters are common. A 2021 CDC v-safe surveillance report documented fatigue in 57% and headache in 46% of Moderna booster recipients [6]. Patients taking lemborexant who experience significant post-COVID-booster fatigue should be counseled about the additive sedation risk on the vaccination evening.

Shingrix (Recombinant Zoster Vaccine)

Shingrix is an adjuvanted recombinant subunit vaccine. The AS01B adjuvant system produces a strong local and systemic inflammatory response by design, which is what generates durable immune memory. As noted above, grade 3 systemic reactions occur in approximately 11% of recipients after the first dose [4]. Fatigue is one of the most frequently reported reactions.

For older adults (the primary Shingrix target population, age 50 and above) who are also more likely to be taking lemborexant for age-related insomnia, the post-Shingrix fatigue night warrants explicit counseling. Clinicians may consider scheduling Shingrix on a Friday or before a day off so patients can monitor their response safely.

Pneumococcal and Other Adult Vaccines

Pneumococcal vaccines (Prevnar 20, Pneumovax 23), Tdap, hepatitis B, and HPV vaccines all follow the same principle: no CYP3A4 interaction, no pharmacokinetic effect on lemborexant. Systemic reactions are generally milder than Shingrix, but the same pharmacodynamic overlay principle applies if a patient feels unwell post-vaccination.

Lemborexant Safety Profile: Clinical Trial Data

The safety and interaction data for lemborexant come primarily from two key phase 3 trials: SUNRISE-1 and SUNRISE-2.

SUNRISE-1 and SUNRISE-2 Key Findings

SUNRISE-1 (N=291) compared lemborexant 5 mg and 10 mg to placebo over 1 month in adults with insomnia disorder [5]. The primary endpoint was subjective sleep onset latency. Both doses outperformed placebo, with the 10 mg dose producing a mean reduction in subjective sleep onset latency of 24.2 minutes versus 12.9 minutes for placebo.

SUNRISE-2 (N=949) extended the assessment to 12 months, adding an active comparator arm of zolpidem extended-release 6.25 mg [7]. Lemborexant 5 mg and 10 mg both demonstrated superior maintenance of sleep compared to zolpidem ER at month 6, with the lemborexant 10 mg arm showing a mean WASO reduction of 29.9 minutes versus 22.7 minutes for zolpidem ER. Residual next-morning sleepiness, assessed by the Karolinska Sleepiness Scale, was lower with lemborexant 5 mg than with zolpidem ER, supporting the clinical relevance of dose selection in patients with next-morning responsibilities.

The Age Factor in Sedation Risk

Adults aged 65 and above showed higher rates of somnolence in clinical trials. The FDA label recommends starting at 5 mg in older adults [2]. This age group also receives the most vaccines (influenza, Shingrix, pneumococcal, COVID-19 boosters). The intersection of older age, lemborexant use, and post-vaccination fatigue represents the highest-risk scenario for transient over-sedation, and it deserves proactive counseling.

Alcohol and Dayvigo: A Closer Look at the Evidence

The FDA label states: "Avoid use with alcohol. Advise patients not to drink alcohol while taking lemborexant" [2]. This is a class-level warning consistent across orexin receptor antagonists; the first approved DORA, suvorexant (Belsomra), carries the same warning [8].

In a crossover pharmacodynamic study, subjects who received lemborexant 10 mg with 0.6 g/kg alcohol (approximately two standard drinks) showed substantially greater impairment on next-morning driving simulations than those who received either substance alone [2]. The study used a standardized driving simulation tool, the Leeds Driving Simulator, and the combined condition produced lane deviation scores consistent with a blood alcohol content of 0.05% to 0.08%, even after the morning-after timepoint when alcohol was nominally cleared.

This finding has direct practical relevance. A patient who has two glasses of wine at dinner, takes 10 mg lemborexant at 11 p.m., and plans to drive to an early medical appointment at 7 a.m. May be functionally impaired at the wheel, despite feeling subjectively alert.

Clinician Counseling Checklist for Patients on Lemborexant

A structured pre-vaccination and general interaction counseling session should cover the following points.

Before any vaccine appointment:

• Inform the vaccinating provider that the patient takes lemborexant.
• Ask whether the vaccine is known to produce significant systemic reactions.
• Plan for the possibility of holding or reducing the lemborexant dose on the vaccination night if a grade 2 or higher reaction occurs.

Alcohol:

• No alcohol on any evening that lemborexant is taken.
• This applies year-round, not just on vaccination days.

New prescriptions:

• Any new antifungal, antibiotic (especially clarithromycin), antiretroviral, or anticonvulsant requires pharmacist and prescriber review before combining with lemborexant.
• Grapefruit and grapefruit juice should be avoided.

Driving:

• Do not drive the morning after lemborexant if feeling residually sedated, if alcohol was consumed the prior evening, or if a significant post-vaccination reaction occurred.

Regulatory and Guideline Context

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for Chronic Insomnia includes a conditional recommendation for the use of suvorexant (the class predecessor). Lemborexant, approved after the guideline publication, is addressed in subsequent AASM position statements as a preferred agent in older adults due to its more favorable next-morning residual profile compared to zolpidem [9]. Neither the AASM nor the CDC vaccine schedules identify any interaction between orexin receptor antagonists and vaccines.

The CDC Adult Immunization Schedule, updated annually, does not list any sleep medication as a contraindication or precaution for any recommended adult vaccine [6]. Clinicians can follow the standard schedule without modification for patients on lemborexant.